Caroli Disease: An Update on Pathogenesis

0
0
0

Caroli Disease: An Update on Pathogenesis

Caroli disease (CD) is a rare congenital disorder characterized by segmental saccular dilatation of the intrahepatic bile ducts. Classified within the spectrum of autosomal recessive polycystic kidney disease (ARPKD), CD is frequently complicated by congenital hepatic fibrosis. Although surgical resection and liver transplantation remain the primary therapeutic options, these interventions address complications rather than halting disease progression. Recent advances in understanding the molecular underpinnings of CD have highlighted the central role of genetic mutations, dysregulated signaling pathways, and structural defects in primary cilia, offering potential avenues for targeted therapies.

Genetic Basis of Caroli Disease
CD arises from loss-of-function mutations in the PKHD1 gene, which encodes fibrocystin/polyductin (FPC). This large transmembrane protein is expressed in renal tubules, bile ducts, pancreatic ducts, and other tissues. In animal models, fibrocystin localizes to primary cilia and basal bodies of cholangiocytes, suggesting its involvement in maintaining ciliary structure and function. Although the precise role of fibrocystin remains incompletely understood, evidence points to its regulatory effects on cellular proliferation, differentiation, cell-matrix interactions, and planar cell polarity (PCP). Homozygous mutations in PKHD1 disrupt these processes, leading to biliary ductal plate malformation, cystogenesis, and progressive hepatic fibrosis.

Mechanisms of Abnormal Cholangiocyte Proliferation and Differentiation
The polycystic kidney (PCK) rat, a validated model of ARPKD and CD, exhibits cholangiocyte hyperproliferation and cystic bile duct dilatation. Studies in this model have identified several dysregulated signaling pathways contributing to disease pathogenesis:

  1. cAMP Pathway Overactivation:
    Cholangiocytes in PCK rats demonstrate elevated cyclic adenosine monophosphate (cAMP) levels, driving excessive proliferation. Octreotide, a somatostatin analog that inhibits cAMP synthesis, reduces liver weights, cyst volumes, and fibrosis indices in PCK rats. This highlights the therapeutic potential of targeting cAMP signaling.

  2. EGF/MEK5/ERK5 Signaling:
    Epidermal growth factor (EGF) pathway activation suppresses developmental apoptosis and promotes cholangiocyte proliferation via the MEK5/extracellular signal-regulated kinase 5 (ERK5) cascade. Gefitinib, an EGFR tyrosine kinase inhibitor, and small-interfering RNAs (siRNAs) targeting MEK5 significantly reduce cholangiocyte proliferation in PCK rats.

  3. Hedgehog (Hh) Pathway:
    Components of the Hh pathway, including Gli1 and Patched1, are upregulated in PCK rats. Cyclopamine, an Hh antagonist, decreases serum alanine aminotransferase (ALT), alkaline phosphatase (ALP), and total liver cyst volumes. However, it does not ameliorate hepatic fibrosis, suggesting fibrosis involves distinct mechanisms.

  4. mTOR Signaling:
    Both mTOR complex 1 (mTORC1) and mTORC2 are hyperactivated in PCK rats and human ARPKD tissues. While rapamycin (an mTORC1 inhibitor) fails to inhibit cystogenesis, NVP-BEZ235, a dual mTORC1/mTORC2 inhibitor, reduces cholangiocyte proliferation, bile duct dilatation, and fibrosis in PCK rats.

  5. Hippo/YAP Pathway:
    Yes-associated protein (YAP), a transcriptional co-activator, is overexpressed in cholangiocytes of PCK rats and ARPKD patients. Verteporfin, a YAP inhibitor, and short hairpin RNAs (shRNAs) targeting YAP suppress cholangiocyte proliferation, implicating Hippo/YAP dysregulation in cyst formation.

  6. IL-8/CTGF Axis:
    CRISPR/Cas9-generated PKHD1-knockout human induced pluripotent stem (iPS) cells differentiate into cholangiocyte-like cells with elevated interleukin-8 (IL-8) expression. IL-8 promotes autocrine cholangiocyte proliferation and connective tissue growth factor (CTGF) production, linking inflammatory signaling to fibrosis progression.

Molecular Drivers of Hepatic Fibrosis
Hepatic fibrosis in CD is driven by transforming growth factor-beta 1 (TGF-β1), which is overexpressed in PCK rat livers. Key mechanisms include:

  1. Macrophage-Mediated Fibrogenesis:
    Activation of the cAMP-protein kinase A (PKA) pathway in cholangiocytes stimulates CXCL10 secretion, recruiting macrophages to the portal microenvironment. These macrophages produce TGF-β1, which perpetuates fibrosis via autocrine and paracrine loops. Clodronate, a macrophage-depleting agent, reduces liver fibrosis and cyst volumes in Pkhd1-mutant mice.

  2. Renin-Angiotensin System (RAS) Activation:
    Angiotensin II promotes hepatic stellate cell activation and TGF-β1 secretion. Telmisartan, an angiotensin receptor blocker, lowers fibrosis indices, Ki-67 (a proliferation marker), and TGF-β1 expression in PCK rats.

  3. PPAR-γ Modulation:
    The peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist pioglitazone inhibits both the MEK5/ERK5 pathway (reducing cholangiocyte proliferation) and TGF-β1 expression (ameliorating fibrosis). This dual effect positions PPAR-γ as a promising therapeutic target.

Primary Cilia Defects and Planar Cell Polarity
Fibrocystin is a structural component of primary cilia, which are mechanosensory organelles critical for biliary development. In PCK rats, cholangiocyte cilia are shortened and malformed, disrupting PCP signaling. PCP proteins ensure oriented cell division along the bile duct axis; their deficiency in ARPKD tissues leads to disordered mitosis, ductal dilatation, and cyst formation.

Emerging Therapeutic Strategies and Future Directions
Current therapeutic candidates for CD, largely tested in preclinical models, target dysregulated pathways:

  • Octreotide: Reduces cAMP-driven proliferation.
  • Gefitinib: Inhibits EGFR/MEK5/ERK5 signaling.
  • NVP-BEZ235: Dual mTORC1/mTORC2 inhibitor.
  • Verteporfin: Suppresses YAP activity.
  • Telmisartan and Pioglitazone: Attenuate fibrosis.

The advent of CRISPR/Cas9 and iPS cell technologies enables disease modeling in human cholangiocytes, overcoming limitations of animal studies. For example, PKHD1-knockout iPS cells have revealed novel roles for IL-8 in cholangiocyte proliferation and fibrosis. Additionally, computational approaches like big data analytics may accelerate drug discovery by identifying pathway intersections or repurposable compounds.

Conclusion
CD pathogenesis is rooted in PKHD1 mutations that impair fibrocystin function, leading to cholangiocyte proliferation, cystogenesis, and hepatic fibrosis. Dysregulation of cAMP, EGF, Hh, mTOR, Hippo/YAP, and TGF-β1 pathways underscores the complexity of this disorder. While animal models have provided critical insights, human cell-based systems and innovative technologies are poised to refine our understanding and expand therapeutic options. Future research must prioritize translational studies to bridge preclinical findings and clinical applications, ultimately improving outcomes for patients with this challenging disease.

doi.org/10.1097/CM9.0000000000001827

Was this helpful?

0 / 0